1. Home
  2. VERU vs YSXT Comparison

VERU vs YSXT Comparison

Compare VERU & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

SELL

Current Price

$2.09

Market Cap

41.9M

Sector

Health Care

ML Signal

SELL

Logo YSX Tech. Co. Ltd Class A Ordinary Shares

YSXT

YSX Tech. Co. Ltd Class A Ordinary Shares

N/A

Current Price

$1.38

Market Cap

41.4M

ML Signal

N/A

Company Overview

Basic Information
Metric
VERU
YSXT
Founded
1971
2011
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Automotive Aftermarket
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
41.9M
41.4M
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
VERU
YSXT
Price
$2.09
$1.38
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $25.67
N/A
AVG Volume (30 Days)
★ 106.8K
3.0K
Earning Date
12-16-2026
07-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $16,296,958.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$5.57
Revenue Growth
N/A
★ N/A
52 Week Low
$2.04
$0.50
52 Week High
$7.33
$2.58

Technical Indicators

Market Signals
Indicator
VERU
YSXT
Relative Strength Index (RSI) 40.86 45.17
Support Level $2.09 $1.21
Resistance Level $2.68 $1.31
Average True Range (ATR) 0.11 0.08
MACD 0.00 -0.02
Stochastic Oscillator 26.67 39.18

Price Performance

Historical Comparison
VERU
YSXT

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares

YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.

Share on Social Networks: